Sinotherapeutics (SH:688247) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-12-09 03:14Core Viewpoint - Shanghai Xuantai Pharmaceutical Technology Co., Ltd. has successfully renewed the inclusion of its product, Sitagliptin Metformin Extended-Release Tablets (II), in the National Medical Insurance Catalog (2025), reflecting the recognition of its clinical value by the National Healthcare Security Administration [1][2]. Group 1: Product Information - The product Sitagliptin Metformin Extended-Release Tablets (II) has been included in the National Medical Insurance Catalog (2025) under a national negotiation renewal format [1]. - The inclusion is expected to enhance the affordability and accessibility of the drug for patients, thereby promoting its market expansion and increasing sales volume [1]. Group 2: Impact on the Company - The renewal of the product's inclusion in the National Medical Insurance Catalog is anticipated to have a positive impact on the company's long-term operational development [1]. - The company plans to actively cooperate in implementing the medical insurance policy to benefit more patients [1]. Group 3: Implementation Timeline - The National Medical Insurance Catalog (2025) will officially take effect on January 1, 2026, with specific details on reimbursement standards and policies to be announced by relevant government departments [2].